^
BIOMARKER:

BARD1 mutation

i
Other names: BRCA1 Associated RING Domain 1, RING-Type E3 Ubiquitin Transferase BARD1, BRCA1-Associated RING Domain Protein 1, BRCA1-Associated RING Domain Gene 1
Entrez ID:
Phase 1b
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
08/12/2019
Primary completion :
06/01/2022
Completion :
06/01/2022
PIK3CA • BRCA1 • BRCA2 • ARID1A • CDK12 • MSH2 • ATRX • POLD1 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PARP1 • XRCC2 • CD4
|
PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)
Phase 2
Shadia Jalal, MD
Recruiting
Last update posted :
10/06/2021
Initiation :
07/09/2019
Primary completion :
05/01/2022
Completion :
05/01/2023
BRCA1 • BRCA2 • ARID1A • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 4
AstraZeneca
Active, not recruiting
Last update posted :
09/29/2021
Initiation :
09/28/2015
Primary completion :
04/17/2020
Completion :
09/20/2021
BRCA1 • BRCA2 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • MUC16 • CHEK1 • RAD54L • BRCA • FANCL • PPP2R2A
|
BRCA1 mutation • BRCA2 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
|
Lynparza (olaparib)
Phase 2
University of Florida
Suspended
Last update posted :
09/27/2021
Initiation :
08/13/2018
Primary completion :
12/01/2022
Completion :
12/01/2023
PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • POLD1 • BRIP1 • CHEK2 • RAD51 • CHEK1 • RAD50 • BARD1 • CDK2 • RAD52 • WRN • BACH1 • FANCG • NBN • PRKDC • RPA1 • ABRAXAS1 • FEN1
|
BARD1 mutation • WRN mutation • RPA1 mutation
|
Zejula (niraparib)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/24/2021
Initiation :
09/20/2021
Primary completion :
03/01/2026
Completion :
03/01/2026
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • BRCA • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
09/16/2021
Initiation :
03/07/2019
Primary completion :
02/01/2023
Completion :
02/01/2023
PD-L1 • BRCA1 • BRCA2 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • FANCA deletion
|
Lynparza (olaparib) • Imfinzi (durvalumab)
Phase 2
Institut fuer Frauengesundheit
Not yet recruiting
Last update posted :
09/03/2021
Initiation :
09/01/2021
Primary completion :
09/01/2023
Completion :
10/01/2025
HER-2 • BRCA1 • PGR • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC
|
BRCA1 mutation • BRCA2 mutation • HER-2 amplification • HER-2 negative • ATM mutation • HRD • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51D mutation • CHEK2 mutation • RAD51C mutation • BARD1 mutation • RAD51 mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
Phase 1
Georgetown University
Recruiting
Last update posted :
09/01/2021
Initiation :
10/13/2017
Primary completion :
08/01/2022
Completion :
08/01/2022
BRCA1 • BRCA2 • PTEN • ARID1A • KMT2D • BAP1 • ATRX • BRIP1 • CHEK2 • FANCA • CHEK1 • RAD50 • BARD1 • MLL2 • WRN • FANCG • NBN • ABRAXAS1
|
BARD1 mutation • WRN mutation
|
carboplatin • Zejula (niraparib)
Phase 1/2
Yonsei University
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
10/01/2021
Primary completion :
12/31/2022
Completion :
05/31/2023
HER-2 • BRCA1 • BRCA2 • HRD • CDK12 • MLH1 • MSH6 • MSH2 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
Phase 2
West Cancer Center
Not yet recruiting
Last update posted :
08/10/2021
Initiation :
08/01/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A • FANCI
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Massachusetts General Hospital
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
01/01/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • RAD54L • BARD1 • PARP1 • XRCC2 • NBN
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 1/2
AstraZeneca
Active, not recruiting
Last update posted :
07/15/2021
Initiation :
03/17/2016
Primary completion :
11/15/2021
Completion :
11/15/2021
HER-2 • BRCA
|
PD-L1 expression • HER-2 negative • CDK12 mutation • BARD1 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab) • Imfinzi (durvalumab)
Phase 2
Southwest Oncology Group
Completed
Last update posted :
06/23/2021
Initiation :
03/03/2017
Primary completion :
01/10/2021
Completion :
04/16/2021
BRCA1 • BRCA2 • HRD • PALB2 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • CHEK1 • RAD54L • BARD1 • FANCF • FANCM • FANCD2 • NBN • RPA1 • FANCC
|
BARD1 mutation • RPA1 mutation
|
Talzenna (talazoparib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
06/07/2021
Initiation :
03/01/2017
Primary completion :
01/01/2022
Completion :
08/01/2022
BRCA1 • BRCA2 • ATM • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
California Pacific Medical Center Research Inst...
Recruiting
Last update posted :
05/03/2021
Initiation :
03/03/2021
Primary completion :
06/30/2023
Completion :
12/31/2024
BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRIP1 • CHEK2 • FANCA • RAD51 • ARID2 • RAD50 • BARD1 • BRCA • FANCD2
|
BRCA1 mutation • BRCA2 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • FANCA mutation • BARD1 mutation • RAD50 mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
Phase 2
University Health Network, Toronto
Recruiting
Last update posted :
04/13/2021
Initiation :
07/19/2016
Primary completion :
06/01/2021
Completion :
12/01/2021
BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • RAD51D • MUC16 • BARD1 • FANCM • PARP1 • PPM1D
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • FANCM mutation • MUC16 expression • PPM1D mutation • RAD51 mutation
|
Lynparza (olaparib)
Phase 2
Clovis Oncology, Inc.
Recruiting
Last update posted :
03/26/2021
Initiation :
11/21/2019
Primary completion :
11/01/2021
Completion :
05/01/2022
BRCA1 • BRCA2 • RAD51B • BRIP1 • FANCA • RAD51 • RAD51C • RAD51D • BARD1 • NBN
|
BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCA deletion • NBN mutation • RAD51 mutation
|
Rubraca (rucaparib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/15/2021
Initiation :
06/03/2019
Primary completion :
03/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
Massachusetts General Hospital
Active, not recruiting
Last update posted :
03/12/2021
Initiation :
01/08/2019
Primary completion :
04/30/2022
Completion :
04/30/2025
BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1 • FANCF • FANCM • NBN • FANCC
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • BRIP1 mutation • FBXW7 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • FANCM mutation • NBN mutation
|
berzosertib (M6620)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
03/11/2021
Initiation :
05/02/2016
Primary completion :
05/31/2041
Completion :
05/31/2042
BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
|
BARD1 mutation
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • NBN mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Fudan University
Not yet recruiting
Last update posted :
08/11/2020
Initiation :
09/01/2020
Primary completion :
02/20/2022
Completion :
04/28/2022
HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • CHEK1 • RAD50 • BARD1 • FANCF • FANCM • WRN • FANCD2 • NBN • FANCC
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • RAD50 mutation • BLM mutation • CHEK1 mutation • HR positive + HER-2 negative • FANCM mutation • NBN mutation • CHEK1 expression
|
Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • pucotenlimab (HX008)
Phase 2
California Pacific Medical Center Research Inst...
Recruiting
Last update posted :
05/18/2020
Initiation :
03/20/2019
Primary completion :
02/01/2021
Completion :
02/01/2023
BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRIP1 • CHEK2 • RAD51 • ARID2 • RAD50 • BARD1 • BRCA • FANCD2
|
BRCA2 mutation • ATM mutation • ARID1A mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • BARD1 mutation • RAD50 mutation
|
Zejula (niraparib)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/31/2020
Initiation :
04/18/2017
Primary completion :
04/18/2021
Completion :
04/18/2022
ER • BRCA1 • PGR • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • MSH2 mutation • RAD51C mutation • BARD1 mutation • MLH1 mutation • PMS2 mutation • RAD51 mutation